Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed
tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE
MRI) are better predictors of response to therapy than the current standard of care (CT or
MRI).